Citations

Citations to this article as recorded by  

• Hemp seed mitigates colonic inflammation through macrophage polarization and microbiota-barrier axis restoration
  Jieun Woo, Dekun Cheng, Erica A. Long, Kristin L. Whitney, Guangyi Shen, Lavanya Reddivari, Qing Jiang, Senay Simsek, Tingting Ju, Weicang Wang
  Food & Function.2026; 17(1): 231.     CrossRef
• Neural regulation of gut inflammation via autonomic nerves: therapeutic implications for inflammatory bowel disease
  Mai Hasegawa, Takaaki Kawaguchi, Hiroki Kiyohara, Toshiaki Teratani, Nobuhiro Nakamoto, Yohei Mikami, Takanori Kanai
  Immunological Medicine.2026; 49(2): 164.     CrossRef
• Evaluation of drug-induced lymphocyte stimulation test in mesalazine-associated allergic drug reaction
  Naoto Fukasawa, Hiroki Kiyohara, Takeya Adachi, Shinya Sugimoto, Yusuke Yoshimatsu, Soichiro Murakami, Ichiro Mizushima, Yuta Kaieda, Kaoru Takabayashi, Junya Tsunoda, Nobuhiro Nakamoto, Koichi Fukunaga, Masataka Taguri, Yohei Mikami, Takanori Kanai
  Journal of Allergy and Clinical Immunology: Global.2026; 5(2): 100625.     CrossRef
• 5-Aminosalicylic Acid-Induced Colitis in a Patient with Rheumatoid Arthritis Without Inflammatory Bowel Disease: A Case Report
  Ryosuke Izumi, Issei Hirata, Yuta Hattori, Yuki Shirane, Hirosato Tamari, Teruo Mori, Makoto Higashiyama, Yoshio Kuga, Takashi Moriya
  Internal Medicine.2026;[Epub]     CrossRef
• Tacrolimus therapy for ulcerative colitis: a retrospective study of factors associated with inducing and maintaining remission
  Ayumi Ito, Shun Murasugi, Miki Koroku, Maria Yonezawa, Teppei Omori, Shinichi Nakamura, Katsutoshi Tokushige, Yousuke Nakai
  BMC Gastroenterology.2026;[Epub]     CrossRef
• Association of Proton Pump Inhibitor and Potassium‐Competitive Acid Blocker Use With Discontinuation and Intolerance of Oral 5‐Aminosalicylic Acid in Patients With Ulcerative Colitis
  Shinsuke Otagiri, Takahiro Ito, Keiji Yagisawa, Ayumu Sugitani, Atsuo Maemoto
  JGH Open.2026;[Epub]     CrossRef
• The Gut-Brain Axis in Comorbidity of Inflammatory Bowel Disease and Anxiety/Depression: Mechanisms, Controversies, and Future Directions
  Yuheng Cui, Yangfeng Huang
  International Journal of General Medicine.2026; Volume 19: 1.     CrossRef
• Comment on “Association of Proton Pump Inhibitor and Potassium‐Competitive Acid Blocker Use With Discontinuation and Intolerance of Oral 5‐Aminosalicylic Acid in Patients With Ulcerative Colitis”
  Bashair Fatima
  Journal of Gastroenterology and Hepatology.2026;[Epub]     CrossRef
• Gut Microbiome Dysbiosis and Inflammatory Bowel Disease Complement Each Other
  Huan Zhang, Jingrong Xiang, Jie Feng, Mengting Zhang, Qinhua Xi
  Digestive Diseases.2025; 43(3): 345.     CrossRef
• Inactivated Cells and Metabolites of Saccharomyces boulardii Alleviate Inflammation Damage in Caco-2 Monolayer Cells and Mice with Ulcerative Colitis
  Yuxin Jin, Zehui Niu, Menglin Feng, Huilian Che, Zhihong Liang
  Antioxidants.2025; 14(6): 737.     CrossRef
• Increasing age at diagnosis raises malignancy risk and aminosalicylate intolerance influences therapeutic strategies in ulcerative colitis: a multicenter I‑BRITE cohort study
  Shintaro Akiyama, Yuka Ito, Mamiko Shiroyama, Satoshi Suzuki, Masanori Ochi, Toshiro Kamoshida, Hiroshi Kashimura, Junichi Iwamoto, Rie Saito, Tsuyoshi Kaneko, Kazuto Ikezawa, Yoshinori Hiroshima, Junji Hattori, Takashi Mamiya, Satoshi Fukuda, Kazuho Iked
  Journal of Gastroenterology.2025; 60(10): 1259.     CrossRef
• Gut microbial healing in IBD: visionary approach or evidence-based reality?
  Linda Nanni, Marco Murgiano, Chieh-En Hsu, Sheida Khalili, Giovanni Cammarota, Alfredo Papa, Antonio Gasbarrini, Franco Scaldaferri, Loris Riccardo Lopetuso
  Expert Review of Gastroenterology & Hepatology.2025; 19(8): 833.     CrossRef
• Effectiveness of granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis and 5-aminosalicylate intolerance
  Masaki Kato, Masaki Yamashita, Shigeki Kojima, Mitsuto Tsukui, Yoshihiko Iijima, Kenichi Araki, Jun Ishida, Takumi Komatsu, Yusuke Nakamoto, Akiyo Kawashima, Maki Konno, Hirofumi Kiyokawa, Yoshinori Sato, Tsutomu Sakurada, Tadateru Maehata, Hiroshi Yasuda
  Medicine.2025; 104(31): e43389.     CrossRef
• Elevated Serum Protease 3 Antineutrophil Cytoplasmic Antibody in Mesalazine-Intolerant Ulcerative Colitis: A Potential Diagnostic Biomarker
  Yuhei Oyama, Takashi Taida, Yoshiki Matsubara, Tomomi Ozaki, Takuya Ohashi, Toshiyuki Ito, Shohei Mukai, Nobuaki Shu, Yushi Koshibu, Yusuke Ozeki, Makoto Furuya, Yukiyo Mamiya, Hayato Nakazawa, Ryosuke Horio, Chihiro Goto, Satsuki Takahashi, Akane Kurosug
  Journal of Clinical Medicine.2025; 14(19): 7019.     CrossRef
• Significance of the drug-induced lymphocyte stimulation test for various oral mesalamines in ulcerative colitis with mesalamine intolerance
  Akira Madarame, Masakatsu Fukuzawa, Kumiko Uchida, Tadashi Ichimiya, Sakiko Naito, Yoshiya Yamauchi, Takashi Morise, Yasuyuki Kagawa, Takahiro Muramatsu, Takao Itoi, Mohammed Misbah Ul Haq
  PLOS One.2025; 20(10): e0334969.     CrossRef
• Lacticaseibacillus rhamnosus MS27 Potentially Prevents Ulcerative Colitis Through Modulation of Gut Microbiota
  Jie Zhang, Jiakun Shen, Linbao Ji, Peng Tan, Chunchen Liu, Xiujun Zhang, Xi Ma
  International Journal of Molecular Sciences.2025; 26(23): 11397.     CrossRef
• Efficacy of 5-aminosalicylic acid continuation versus discontinuation in patients with ulcerative colitis escalated to advanced therapy: a systematic review and meta-analysis of adjusted effect estimates
  Hyun Hee Sul, Douglas Mesadri Gewehr, Hara Kang, Odery Ramos, Ryan C Ungaro, Charles N Bernstein
  Journal of Crohn's and Colitis.2025;[Epub]     CrossRef
• Drug-induced Interstitial Nephritis in a Patient with Ulcerative Colitis Treated with 5-Aminosalicylic Acid
  Daichi Hayashi, Tsutomu Nishida, Naoto Osugi, Yasuo Kusunoki, Satoru Okabe, Yoshifumi Fujii, Dai Nakamatsu, Kengo Matsumoto, Masashi Yamamoto, Koji Fukui
  Internal Medicine.2024; 63(8): 1081.     CrossRef
• The impact of 5-aminosalicylates on the efficacy of mesenchymal stem cell therapy in a murine model of ulcerative colitis
  Huanhuan Chen, Huimin Wang, XiaoJing Xu, Ya'nan Hu, Jing Su, Dongdong Li, Zimu Li, Shixiang Feng, Jinming Liu, Huanxiang Zhang, Xiaoyan Wang
  International Immunopharmacology.2024; 134: 112255.     CrossRef
• Characteristics of Mucosa-Associated Microbiota in Ulcerative Colitis Patients with 5-Aminosalicylic Acid Intolerance
  Hiroshi Matsumoto, Momoyo Sasahira, Tei Tei Go, Shogen Yo, Takehiro Ninomiya, Motoyasu Osawa, Osamu Handa, Eiji Umegami, Ryo Inoue, Akiko Shiotani
  Biomedicines.2024; 12(9): 2125.     CrossRef
• Lithium Coupled with C6-Carboxyl Improves the Efficacy of Oligoguluronate in DSS-Induced Ulcerative Colitis in C57BL/6J Mice
  Jiayi Li, Meng Shao, Hao Liu, Peng Guo, Fei Liu, Mingfeng Ma, Quancai Li
  Marine Drugs.2024; 22(12): 573.     CrossRef
• Persistence of newly prescribed 5-aminosalicylic acid in patients with ulcerative colitis: A nationwide comprehensive database study
  Tatsuya Noda, Kotaro Kuwaki, Munehito Machida, Yasuyuki Okumura, Yuichi Nishioka, Tomoya Myojin, Tomoaki Imamura, Barry Kweh
  PLOS ONE.2024; 19(12): e0316181.     CrossRef
• Manipulating Microbiota in Inflammatory Bowel Disease Treatment: Clinical and Natural Product Interventions Explored
  Mengjie Zhu, Yijie Song, Yu Xu, Hongxi Xu
  International Journal of Molecular Sciences.2023; 24(13): 11004.     CrossRef
• Risk factors for intolerance of oral 5‐aminosalicylic acid preparations in pediatric ulcerative colitis
  Naoki Abe, Naomi Iwata, Ryuhei Yasuoka, Daisuke Nishida, Asami Oohara, Haruna Nakaseko, Shiro Sugiura, Shinji Kawabe
  Pediatrics International.2023;[Epub]     CrossRef
• CURRENT STATUS, PROBLEMS AND PROSPECTS OF ULCERATIVE COLITIS MEDICAL CORRECTION (LITERATURE REVIEW)
  T. O. Briukhanova, O. A. Nakonechna, O. V Babenko
  Bulletin of Problems Biology and Medicine.2023; 1(3): 28.     CrossRef
• Significance of 5-Aminosalicylic Acid Intolerance in the Clinical Management of Ulcerative Colitis
  Yohei Mikami, Junya Tsunoda, Shohei Suzuki, Ichiro Mizushima, Hiroki Kiyohara, Takanori Kanai
  Digestion.2023; 104(1): 58.     CrossRef
• Genetic Background of Mesalamine-induced Fever and Diarrhea in Japanese Patients with Inflammatory Bowel Disease
  Kaoru Suzuki, Yoichi Kakuta, Takeo Naito, Tetsuya Takagawa, Hiroyuki Hanai, Hiroshi Araki, Yu Sasaki, Hirotake Sakuraba, Makoto Sasaki, Tadakazu Hisamatsu, Satoshi Motoya, Takayuki Matsumoto, Motoyuki Onodera, Yoh Ishiguro, Hiroshi Nakase, Akira Andoh, Sa
  Inflammatory Bowel Diseases.2022; 28(1): 21.     CrossRef
• Classification and clinical features of adverse drug reactions in patients with ulcerative colitis treated with 5‐aminosalicylate acid: a single-center, observational study
  Yuri Tsujii, Tsutomu Nishida, Naoto Osugi, Yoshifumi Fujii, Aya Sugimoto, Dai Nakamatsu, Kaori Mukai, Kengo Matsumoto, Shiro Hayashi, Masashi Yamamoto, Sachiko Nakajima
  Scandinavian Journal of Gastroenterology.2022; 57(2): 190.     CrossRef
• The Prognostic Value of Residual Nonrectal Inflammation in Ulcerative Colitis
  Eun Ae Kang
  Gut and Liver.2022; 16(3): 487.     CrossRef
• Personalized medicine in inflammatory bowel disease: Perspectives on Asia
  Su Hyun Park, Sang Hyoung Park
  Journal of Gastroenterology and Hepatology.2022; 37(8): 1434.     CrossRef
• Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
  Jihye Park, Jae Hee Cheon
  The Korean Journal of Internal Medicine.2022; 37(5): 895.     CrossRef
• The emerging microbiome‐based approaches to IBD therapy: From SCFAs to urolithin A
  Mohammad Rudiansyah, Saade Abdalkareem Jasim, Bakhadir S. Azizov, Vadim Samusenkov, Walid Kamal Abdelbasset, Ghulam Yasin, Hawraa Jabbar Mohammad, Mohammed Abed Jawad, Trias Mahmudiono, Seyed Reza Hosseini‐Fard, Rasoul Mirzaei, Sajad Karampoor
  Journal of Digestive Diseases.2022; 23(8-9): 412.     CrossRef
• Multicenter survey on mesalamine intolerance in patients with ulcerative colitis
  Sakiko Hiraoka, Akiko Fujiwara, Tatsuya Toyokawa, Reiji Higashi, Yuki Moritou, Shinjiro Takagi, Kazuhiro Matsueda, Seiyuu Suzuki, Jiro Miyaike, Toshihiro Inokuchi, Masahiro Takahara, Jun Kato, Hiroyuki Okada
  Journal of Gastroenterology and Hepatology.2021; 36(1): 137.     CrossRef
• Enteric-coated gelatin nanoparticles mediated oral delivery of 5-aminosalicylic acid alleviates severity of DSS-induced ulcerative colitis
  Anas Ahmad, Md. Meraj Ansari, Rakesh Kumar Mishra, Ajay Kumar, Akshay Vyawahare, Rahul Kumar Verma, Syed Shadab Raza, Rehan Khan
  Materials Science and Engineering: C.2021; 119: 111582.     CrossRef
• Bacteriotherapy for inflammatory bowel disease
  Yusuke Yoshimatsu, Yohei Mikami, Takanori Kanai
  Inflammation and Regeneration.2021;[Epub]     CrossRef
• Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
  You Sun Kim
  Journal of the Korean Medical Association.2021; 64(9): 596.     CrossRef
• The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies
  Yu Hu, Zhen Ye, Mingquan Wu, Yingqi She, Linzhen Li, Yujie Xu, Kaihua Qin, Zhipeng Hu, Maoyi Yang, Fating Lu, Qiaobo Ye
  Frontiers in Medicine.2021;[Epub]     CrossRef
• Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
  Ji Young Chang, Jae Hee Cheon
  Precision and Future Medicine.2021; 5(4): 151.     CrossRef
• 5‐aminosalicylate–intolerant patients are at increased risk of colectomy for ulcerative colitis
  Shuji Hibiya, Yusuke Matsuyama, Toshimitsu Fujii, Chiaki Maeyashiki, Eiko Saito, Kimiko Ito, Hiromichi Shimizu, Ami Kawamoto, Maiko Motobayashi, Kento Takenaka, Masakazu Nagahori, Masayuki Kurosaki, Tsunehito Yauchi, Kazuo Ohtsuka, Takeo Fujiwara, Ryuichi
  Alimentary Pharmacology & Therapeutics.2021; 53(1): 103.     CrossRef
• Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease
  Satohiro Matsumoto, Hirosato Mashima
  Scientific Reports.2020;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Squid cartilage-derived chondroitin sulfate from Uroteuthis chinensis: a novel marine prebiotic modulating gut microbiota and ameliorating ulcerative colitis
  Shiwei Chen, Hanjing Li, Rongkun Chen, Zihua Liang, Zongjie Ou, Pengzhe Zhang, Li Ni, Jiacong Deng, Xucong Lv
  Food Research International.2026; 235: 119141.     CrossRef
• Systemic investigation of the mechanism underlying the therapeutic effect of Astragalus membranaceus in ulcerative colitis
  Jingxin Mao, Lihong Tan, Cheng Tian, Wenxiang Wang, YanLin Zou, Zhaojing Zhu, Yan Li
  The American Journal of the Medical Sciences.2025; 369(2): 238.     CrossRef
• Hepatoprotective Effects of Resveratrol on Acetaminophen-Induced Acute Liver Injury and Its Implications for Tofacitinib Disposition in Rats
  Hyeon Gyeom Choi, So Yeon Park, Sung Hun Bae, Sun-Young Chang, So Hee Kim
  Biomolecules & Therapeutics.2025; 33(3): 501.     CrossRef
• Evaluation of Indigo Naturalis Prepared Using a Novel Method: Therapeutic Effects on Experimental Ulcerative Colitis in Mice
  Xianxiang Xu, Lin Lin, Wenjie Ning, Xinyi Zhou, Aftab Ullah, Huiyong Yang, Xunxun Wu, Yong Diao
  Pharmaceutics.2025; 17(5): 674.     CrossRef
• Physiologically Based Pharmacokinetic Simulation of Tofacitinib in Humans Using Extrapolation from Single-Species Renal Failure Model
  Sung Hun Bae, So Yeon Park, Hyeon Gyeom Choi, So Hee Kim
  Pharmaceutics.2025; 17(7): 914.     CrossRef
• Modulation of tofacitinib pharmacokinetics by isosakuranetin in streptozotocin-induced diabetic rats
  Hyeon Gyeom Choi, Sung Hun Bae, So Yeon Park, Hyoungsu Kim, Sun-Young Chang, So Hee Kim
  Journal of Pharmaceutical Investigation.2025;[Epub]     CrossRef
• Development of Validated RP-UHPLC and Analogous UV Spectroscopic Methods for the Analysis of Tofacitinib Citrate
  Jahid Hossain, Diponkor Kumar Shill, Kausik Chandra Mondal, Abu Shara Shamsur Rouf, Uttom Kumar
  Drug Analytical Research.2025; 9(2): 48.     CrossRef
• Histologic features and predicting prognosis in ulcerative colitis patients with mild endoscopic activity
  Seung Yong Shin, Hee Sung Kim, Kisung Kim, Chang Won Choi, Jung Min Moon, Jeong Wook Kim, Hyun Jin Joo, Jeongkuk Seo, Muhyeon Sung, Chang Hwan Choi
  The Korean Journal of Internal Medicine.2024; 39(1): 68.     CrossRef
• Recent Updates on the Therapeutics Benefits, Clinical Trials, and Novel Delivery Systems of Chlorogenic Acid for the Management of Diseases with a Special Emphasis on Ulcerative Colitis
  Ranjit K. Harwansh, Hemant Bhati, Rohitas Deshmukh
  Current Pharmaceutical Design.2024; 30(6): 420.     CrossRef
• Dose-dependent effects of cobalt chloride supplementation in a rat model of acetic acid-induced ulcerative colitis
  Akinleye Stephen Akinrinde, Ekundayo Stephen Samuel, Bisi Olajumoke Adeoye
  Comparative Clinical Pathology.2024; 33(5): 705.     CrossRef
• Pharmacogenetics in personalized treatment in pediatric patients with inflammatory bowel disease (IBD)
  Daniela Kosorínová, Pavlína Suchá, Zuzana Havlíčeková, Marek Pršo, Pavol Dvoran, Peter Bánovčin
  Česko-slovenská pediatrie.2024; 79(4): 213.     CrossRef
• Long‐term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow‐up in the SELECTION open‐label long‐term extension study
  Brian G. Feagan, Katsuyoshi Matsuoka, Gerhard Rogler, David Laharie, Séverine Vermeire, Silvio Danese, Edward V. Loftus, Ian Beales, Stefan Schreiber, Hyo Jong Kim, Margaux Faes, Angela de Haas, Tomasz Masior, Christine Rudolph, Laurent Peyrin‐Biroulet
  Alimentary Pharmacology & Therapeutics.2024; 60(5): 563.     CrossRef
• Loganin Ameliorates Acute Kidney Injury and Restores Tofacitinib Metabolism in Rats: Implications for Renal Protection and Drug Interaction
  Hyeon Gyeom Choi, So Yeon Park, Sung Hun Bae, Sun-Young Chang, So Hee Kim
  Biomolecules & Therapeutics.2024; 32(5): 601.     CrossRef
• Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets
  Han Na Oh, Seung Yong Shin, Jong-Hwa Kim, Jihye Baek, Hyo Jong Kim, Kang-Moon Lee, Soo Jung Park, Seok-Young Kim, Hyung-Kyoon Choi, Wonyong Kim, Woo Jun Sul, Chang Hwan Choi
  Gut Pathogens.2024;[Epub]     CrossRef
• Protective effect of (E)-(2,4-dihydroxy)-α-aminocinnamic acid, a hydroxy cinnamic acid derivative, in an ulcerative colitis model induced by TNBS
  Astrid Mayleth Rivera Antonio, Itzia Irene Padilla Martínez, Yazmín Karina Márquez-Flores, Alan Hipólito Juárez Solano, Mónica A. Torres Ramos, Martha Cecilia Rosales Hernández
  Bioscience Reports.2024;[Epub]     CrossRef
• Lactiplantibacillus plantarum BW2013 protects mucosal integrity and modulates gut microbiota of mice with colitis
  Xiaohui Niu, Qian Li, Na Luan, Jia Liu, Michael Zhang, Jun An, Zuming Li, Zhihui Bai, Ran Xia, Zhichao Wu
  Canadian Journal of Microbiology.2023; 69(4): 158.     CrossRef
• Reviewing not Homer’s Iliad, but “Kai Bao Ben Cao”: indigo dye—the past, present, and future
  Yusuke Yoshimatsu, Tomohisa Sujino, Takanori Kanai
  Intestinal Research.2023; 21(2): 174.     CrossRef
• Effect and mechanism of total ginsenosides repairing SDS‑induced Drosophila enteritis model based on MAPK pathway
  Hang Su, Yujing Tan, Zhijiang Zhou, Chunjuan Wang, Wei Chen, Jinlong Wang, Haiming Sun
  Experimental and Therapeutic Medicine.2023;[Epub]     CrossRef
• Effects of Hyperlipidemia on the Pharmacokinetics of Tofacitinib, a JAK 1/3 Inhibitor, in Rats
  Jong Mun Won, Hyeon Gyeom Choi, So Yeon Park, Jang-Hee Kim, So Hee Kim
  Pharmaceutics.2023; 15(9): 2195.     CrossRef
• Knowledge, attitude, and practice of patients living with inflammatory bowel disease: A cross-sectional study
  Xiao-Xiao Shao, Lu-Yan Fang, Xu-Ri Guo, Wei-Zhong Wang, Rui-Xin Shi, Dao-Po Lin
  World Journal of Gastroenterology.2023; 29(43): 5818.     CrossRef
• Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy
  Danny Con, Bridgette Andrew, Steven Nicolaides, Daniel R van Langenberg, Abhinav Vasudevan
  Intestinal Research.2022; 20(1): 101.     CrossRef
• Efficacy of sigmoidoscopy for evaluating disease activity in patients with ulcerative colitis
  Su Bum Park, Seong-Jung Kim, Jun Lee, Yoo Jin Lee, Dong Hoon Baek, Geom Seog Seo, Eun Soo Kim, Sang-Wook Kim, So Yeong Kim
  BMC Gastroenterology.2022;[Epub]     CrossRef
• Protective effects of Ligularia fischeri root extracts against ulcerative colitis in mice through activation of Bcl-2/Bax signalings
  Yong-Ping Fu, Huan Yuan, Yan Xu, Ru-Ming Liu, Yi Luo, Jian-Hui Xiao
  Phytomedicine.2022; 99: 154006.     CrossRef
• Traditional Chinese Medicine Alleviates Ulcerative Colitis via Modulating Gut Microbiota
  Wan Feng, Lei Zhu, Hong Shen, Jin-Yi Wan
  Evidence-Based Complementary and Alternative Medicine.2022; 2022: 1.     CrossRef
• Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics after Anti-HBV Treatment
  Soo Min Ahn, Jonggi Choi, Byong Duk Ye, Suk-Kyun Yang, Ji Seon Oh, Yong‑Gil Kim, Chang-Keun Lee, Bin Yoo, Sang Hyoung Park, Seokchan Hong
  Gut and Liver.2022; 16(4): 567.     CrossRef
• Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
  Kyuwon Kim, Hee Seung Hong, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye, Sang Hyoung Park
  The Korean Journal of Internal Medicine.2022; 37(6): 1140.     CrossRef
• “Two-birds-one-stone” colon-targeted nanomedicine treats ulcerative colitis via remodeling immune microenvironment and anti-fibrosis
  Jiaxin Zhang, Ante Ou, Xueping Tang, Rong Wang, Yujuan Fan, Yuefei Fang, Yuge Zhao, Pengfei Zhao, Dongying Chen, Bing Wang, Yongzhuo Huang
  Journal of Nanobiotechnology.2022;[Epub]     CrossRef
• Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis
  Soo-Kyung Park, Sang-Bum Kang, SangSoo Kim, Tae Oh Kim, Jae Myung Cha, Jong Pil Im, Chang Hwan Choi, Eun Soo Kim, Geom Seog Seo, Chang Soo Eun, Dong Soo Han, Dong Il Park
  The Korean Journal of Internal Medicine.2022; 37(5): 949.     CrossRef
• Effects of Dextran Sulfate Sodium-Induced Ulcerative Colitis on the Disposition of Tofacitinib in Rats
  Sung Hun Bae, Hyo Sung Kim, Hyeon Gyeom Choi, Sun-Young Chang, So Hee Kim
  Biomolecules & Therapeutics.2022; 30(6): 510.     CrossRef
• Effects of Isosakuranetin on Pharmacokinetic Changes of Tofacitinib in Rats with N-Dimethylnitrosamine-Induced Liver Cirrhosis
  Sung Hun Bae, Hyeon Gyeom Choi, So Yeon Park, Sun-Young Chang, Hyoungsu Kim, So Hee Kim
  Pharmaceutics.2022; 14(12): 2684.     CrossRef
• Trends in Corticosteroid Prescriptions for Ulcerative Colitis and Factors Associated with Long-Term Corticosteroid Use: Analysis Using Japanese Claims Data from 2006 to 2016
  Katsuyoshi Matsuoka, Ataru Igarashi, Noriko Sato, Yuri Isono, Maki Gouda, Katsuhiko Iwasaki, Ayako Shoji, Tadakazu Hisamatsu
  Journal of Crohn's and Colitis.2021; 15(3): 358.     CrossRef
• Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis
  Yong Il Lee, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
  Gut and Liver.2021; 15(2): 232.     CrossRef
• Efficacy and Safety of Fecal Microbiota Transplantation and Prospect of Microbe-based Therapies for Inflammatory Bowel Disease
  Hoon Gil Jo, Geom Seog Seo
  The Korean Journal of Gastroenterology.2021; 78(1): 31.     CrossRef
• The Clinical Features of Inflammatory Bowel Disease in Patients with Obesity
  Seong Kyun Kim, Ho-Su Lee, Beom-Jun Kim, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park, Masanao Nakamura
  Canadian Journal of Gastroenterology and Hepatology.2021;[Epub]     CrossRef
• Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
  You Sun Kim
  Journal of the Korean Medical Association.2021; 64(9): 596.     CrossRef
• Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study
  Joo Hye Song, Eun Ae Kang, Soo-Kyung Park, Sung Noh Hong, You Sun Kim, Ki Bae Bang, Kyeong Ok Kim, Hong Sub Lee, Sang-Bum Kang, Seung Yong Shin, Eun Mi Song, Jong Pil Im, Chang Hwan Choi
  Gut and Liver.2021; 15(5): 752.     CrossRef
• Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies
  Hyo Yeop Song, Geom Seog Seo
  Journal of the Korean Medical Association.2021; 64(9): 605.     CrossRef
• Current status of inflammatory bowel diseases in Korea
  Suk-Kyun Yang
  Journal of the Korean Medical Association.2021; 64(9): 572.     CrossRef
• Intestinal microbiota and inflammatory bowel diseases
  Chang Soo Eun
  Journal of the Korean Medical Association.2021; 64(9): 588.     CrossRef
• Does cytomegalovirus load predict the outcome of acute severe ulcerative colitis?
  You Sun Kim
  Intestinal Research.2021; 19(4): 357.     CrossRef
• Clinical Course of COVID-19 in Patients with Inflammatory Bowel Disease in Korea: a KASID Multicenter Study
  Jin Wook Lee, Eun Mi Song, Sung-Ae Jung, Sung Hoon Jung, Kwang Woo Kim, Seong-Joon Koh, Hyun Jung Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
  Journal of Korean Medical Science.2021;[Epub]     CrossRef
• Development of a Machine Learning Model to Distinguish between Ulcerative Colitis and Crohn’s Disease Using RNA Sequencing Data
  Soo-Kyung Park, Sangsoo Kim, Gi-Young Lee, Sung-Yoon Kim, Wan Kim, Chil-Woo Lee, Jong-Lyul Park, Chang-Hwan Choi, Sang-Bum Kang, Tae-Oh Kim, Ki-Bae Bang, Jaeyoung Chun, Jae-Myung Cha, Jong-Pil Im, Kwang-Sung Ahn, Seon-Young Kim, Dong-Il Park
  Diagnostics.2021; 11(12): 2365.     CrossRef
• Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
  Ji Young Chang, Jae Hee Cheon
  Precision and Future Medicine.2021; 5(4): 151.     CrossRef
• Intestinal Epithelial Deletion of Sphk1 Prevents Colitis-Associated Cancer Development by Inhibition of Epithelial STAT3 Activation
  Seung Bin Park, Byung-il Choi, Beom Jae Lee, Nam Joo Kim, Yoon A. Jeong, Moon Kyung Joo, Hyo Jung Kim, Jong-Jae Park, Jae Seon Kim, Yoon-Seok Noh, Hyun Joo Lee
  Digestive Diseases and Sciences.2020; 65(8): 2284.     CrossRef
• Simple determination and quantification of tofacitinib, a JAK inhibitor, in rat plasma, urine and tissue homogenates by HPLC and its application to a pharmacokinetic study
  Ji Eun Kim, Mun Young Park, So Hee Kim
  Journal of Pharmaceutical Investigation.2020; 50(6): 603.     CrossRef
• Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats
  Eun Hye Gwak, Hee Young Yoo, So Hee Kim
  Biomolecules & Therapeutics.2020; 28(4): 361.     CrossRef
• Slower Elimination of Tofacitinib in Acute Renal Failure Rat Models: Contribution of Hepatic Metabolism and Renal Excretion
  Sung Hun Bae, Sun-Young Chang, So Hee Kim
  Pharmaceutics.2020; 12(8): 714.     CrossRef
• The amelioration of ulcerative colitis induced by Dinitrobenzenesulfonic acid with Radix Hedysari
  Gengen Shi, Donghan Wang, Zhiyuan Xue, Xianglin Zhou, Yaoyao Fang, Shilan Feng, Lianggong Zhao
  Journal of Food Biochemistry.2020;[Epub]     CrossRef
• Dose-Dependent Pharmacokinetics of Tofacitinib in Rats: Influence of Hepatic and Intestinal First-Pass Metabolism
  Ji Sang Lee, So Hee Kim
  Pharmaceutics.2019; 11(7): 318.     CrossRef
• Dermatologische Komplikationen unter Therapie mit Biologika bei entzündlichen Autoimmunerkrankungen
  Wiebke Sondermann, Saskia Herz, Elsa Sody, Andreas Körber
  JDDG: Journal der Deutschen Dermatologischen Gesellschaft.2019; 17(10): 1029.     CrossRef
• Dermatological complications of therapy with biologics in inflammatory autoimmune diseases
  Wiebke Sondermann, Saskia Herz, Elsa Sody, Andreas Körber
  JDDG: Journal der Deutschen Dermatologischen Gesellschaft.2019; 17(10): 1029.     CrossRef